Form 4: Stevens Christopher James reports acquisition/exercise transactions in RCKT

Rhea-AI Filing Summary

Stevens Christopher James reported acquisition or exercise transactions in a Form 4 filing for RCKT. The filing lists transactions totaling 155,000 shares. Following the reported transactions, holdings were 93,037 shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Stevens Christopher James

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	93,037	$0.00	--
Grant/Award	Common Stock	61,963	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 93,037 shares (Direct); Common Stock — 469,129 shares (Direct)

Footnotes (1)

1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years. This option represents a right to purchase a total of 93,037 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stevens Christopher James

(Last) (First) (Middle)

C/O ROCKET PHARMACEUTICALS, INC.

9 CEDARBROOK DRIVE

(Street)

CRANBURY NJ 08512

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	02/11/2026		A		61,963(2)	A	$0	469,129(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.24	02/11/2026		A		93,037		(3)	02/11/2036	Common Stock	93,037	$0	93,037	D

Explanation of Responses:

1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

2. Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years.

3. This option represents a right to purchase a total of 93,037 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

	/s/ Martin Wilson, as attorney-in-fact for Christopher James Stevens	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Rocket Pharmaceuticals (RCKT) report?

Rocket Pharmaceuticals reported equity awards to its Chief Operating Officer. He received 61,963 restricted stock units and a stock option for 93,037 shares, both granted at $0 cost, with vesting starting February 11, 2027 and continuing over two years.

How many Rocket Pharmaceuticals (RCKT) shares did the COO acquire?

The COO acquired 61,963 shares of common stock through restricted stock units. Following this grant, his beneficial ownership of Rocket Pharmaceuticals common stock increased to 469,129 shares, as disclosed in the Form 4 insider transaction report filed under Section 16 rules.

What stock options were granted to the Rocket Pharmaceuticals (RCKT) COO?

He was granted a stock option to purchase 93,037 Rocket Pharmaceuticals common shares at an exercise price of $3.24. The option vests one-third on February 11, 2027, with the balance vesting in equal quarterly installments over the subsequent two years.

What is the vesting schedule for the Rocket Pharmaceuticals (RCKT) COO’s RSUs?

The 61,963 RSUs vest one-third on February 11, 2027, with remaining shares vesting in equal quarterly installments over the next two years. This staggered schedule ties continued stock delivery to the executive’s ongoing employment with Rocket Pharmaceuticals.

What is the vesting schedule for the Rocket Pharmaceuticals (RCKT) COO’s stock option?

The option for 93,037 shares vests one-third on February 11, 2027. The remaining two-thirds vest in equal quarterly installments over the following two years, and the option expires on February 11, 2036 if not exercised according to the grant terms.

At what prices were the Rocket Pharmaceuticals (RCKT) equity awards granted?

The restricted stock units were granted at $0, meaning no cash payment is required to receive the underlying shares upon vesting. The stock option has an exercise price of $3.24 per share, which must be paid to purchase Rocket Pharmaceuticals common stock when exercised.